Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Grows By 135.3%

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the target of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 33,385 shares, a growth of 135.3% from the January 29th total of 14,187 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average trading volume of 101,537 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 101,537 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the shares of the company are short sold.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $2.66 on Friday. The stock has a fifty day moving average price of $2.76 and a 200 day moving average price of $2.82. The stock has a market cap of $36.04 million, a PE ratio of -0.56 and a beta of 0.46. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $5.60.

Institutional Investors Weigh In On OnKure Therapeutics

A number of large investors have recently added to or reduced their stakes in OKUR. XTX Topco Ltd purchased a new position in OnKure Therapeutics during the 4th quarter valued at about $52,000. ADAR1 Capital Management LLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth approximately $2,941,000. Kotler Kevin acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth approximately $573,000. Barclays PLC lifted its stake in OnKure Therapeutics by 4,286.8% in the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares in the last quarter. Finally, Prosight Management LP grew its holdings in OnKure Therapeutics by 204.9% during the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after buying an additional 548,950 shares during the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on OKUR. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded OnKure Therapeutics to a “sell” rating in a research note on Saturday, November 1st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OnKure Therapeutics currently has an average rating of “Hold” and a consensus price target of $32.00.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.